ad image

GSK

1 / 3
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Pharma's Almanac

PAO-06-022--RT-01Jun 24, 2022
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Industry Challenges

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Pharma's Almanac

O-06-022--RT-01Jun 24, 2022
GSK
Expansion

GSK Unveils Plan for One of Europe’s Largest Life Science Campuses in Stevenage

GSK

PR-M07-21-08Jul 19, 2021
GSK
Collaboration

ViiV Healthcare and Halozyme Enter Global Collaboration for ENHANZE® Drug Delivery Technology to Enable Development of “Ultra Long-Acting” Medicines for HIV

GSK

PR-M06-21-032Jun 25, 2021
Sanofi
COVID-19 Vaccine

Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 Trial

Sanofi

PR-M05-21-011May 17, 2021
GSK
Clinical Trials

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data From the Phase 2 Blaze-4 Trial Evaluating Bamlanivimab With Vir-7831 in Low-risk Adults With Covid-19

GSK

PR-M04-21-004-1045Apr 02, 2021
GSK

GSK to Support Manufacture of Novavax’ COVID-19 Vaccine

GSK

PR-M04-21-002Apr 01, 2021
GSK
COVID-19 Vaccine

Sanofi and GSK to Support COVAX with 200 Million Doses of COVID-19 Vaccine

GSK

PR-M10-20-18Oct 28, 2020
FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
FDA Approval

FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

PR-M08-20-NI-11Aug 06, 2020
Sanofi
COVID-19 Vaccine Funding

Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 Vaccine

Sanofi

PR-M08-20-NI-05Jul 31, 2020
GSK
COVID-19 Vaccine Collaboration

GSK and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Candidate Vaccine

GSK

PR-M07-20-NI-009Jul 07, 2020
GSK
HIV

ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP

GSK

PR-M05-20-NI-034-1543May 22, 2020
GSK

FDA Approves GSK's Zejula

GSK

PR-M05-20-NI-014May 08, 2020
Sanofi

Sanofi and GSK to Join Forces in COVID-19 Vaccine Collaboration

Sanofi

PR-M04-20-NI-020Apr 14, 2020
GSK

GSK's Asthma Biologic Approved

GSK

PR-M04-20-NI-007Apr 03, 2020
Bora Pharmaceuticals
M&A

Bora Pharmaceuticals to Acquire GSK Mississauga-based Facility

Bora Pharmaceuticals

PR-M03-20-NI-018Mar 12, 2020
Immatics
Partnership

Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies

Immatics

PR-M02-20-NI-025Feb 20, 2020
GSK
Vaccine

CEPI and GSK Collaborate to Develop a Vaccine for Coronavirus

GSK

PR-M02-20-NI-001Feb 04, 2020
GSK
Vaccine

GSK Candidate Vaccine Demonstrates Sustained Level of Protection Against Active Pulmonary Tuberculosis

GSK

PR-M10-19-NI-040Oct 29, 2019
GSK
Divest

GSK Agrees to Divest Rabies and Tick-Borne Encephalitis Vaccines to Bavarian Nordic

GSK

PR-M10-19-NI-038Oct 25, 2019
1 / 3